Bixiye
QP45-21 Medical Drug Update for Botulinum Toxins (Myobloc, Botox, Dysport, Xeomin) - Commercial Products
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2151 - 2160 ee natiijooyinka 3167
Bixiye
QP46-21 Incorrect ID Cards Issued for Minnesota Health Care Programs Members
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Bixiye
QP43-21 MHCP Pharmacy Benefit Exclusion for Jemperli and Zynlonta™
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Bixiye
QP44-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Zeposia® (ozanimod)
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Bixiye
2021 June Provider Press
Taariikhda uu dhaqangalayo Barnaamijka: May 25, 2021
Bixiye
QP41-21 Commercial and MHCP Pharmacy Benefit Exclusion for Qutenza®
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021
Bixiye
QP40-21 Commercial Pharmacy Benefit Update – New and Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective July 1, 2021
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021
Bixiye
QP42-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia Agents
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021
Bixiye
P31-21 eviCore Healthcare Specialty Utilization Management (UM) Program – Laboratory Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021
Bixiye
P30-21 eviCore Healthcare Specialty Utilization Management (UM) Program - Cardiology and Radiology Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: May 03, 2021